SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) — iBio, I c. (NASDAQ: IBIO), a cli ical-stage biotech ology compa y developi g lo g-acti g a tibody the apeutics fo obesity, ca diometabolic a d ca diopulmo a y diseases, today a ou ced its fi a cial esults fo the fi st qua te of fiscal yea 2027, e ded Septembe 30, 2026, a d p ovided a co po ate update o its p og ess.
“This was a qua te of focus a d executio as we adva ced ou po tfolio of lo g-acti g a tibody the apeutics desig ed to add ess impo ta t challe ges i obesity ca e,” said Ma ti B e e , DVM, Ph.D., Chief Executive Office a d Chief Scie tific Office of iBio. “The data p ese ted at EASD st e gthe ou co victio i IBIO-610’s pote tial to delive high-quality weight loss a d p ovide impo ta t p ecli ical validatio as we adva ce towa d a IND-equivale t fili g by the e d of 2026, with pla s to i itiate fi st-i -huma studies i the fi st half of 2027. We also a ticipate adva ci g IBIO-600 i the multiple asce di g dose po tio of the Phase 1 t ial i the fi st qua te of 2027 a d p og essi g ou p ecli ical p og ams that aim to add ess the e ti e spect um of ca diometabolic disease ca e. Togethe , this p og ess b i gs us close to ou b oade goal of helpi g people livi g with obesity achieve high-quality weight loss a d bette lo g-te m health.”
- P ese ted additio al p ecli ical body compositio data f om a study of IBIO-610, iBio’s lo g-acti g Activi E a tibody, i obese o -huma p imates (NHPs) at the Eu opea Associatio fo the Study of Diabetes (EASD) A ual Meeti g o Octobe 1st.
- At week eight, fat accou ted fo 93% of the weight lost by NHPs eceivi g IBIO-610 i combi atio with semaglutide, compa ed with 77% fo NHPs eceivi g semaglutide alo e. Lea mass accou ted fo 6% a d 22% of weight lost, espectively.
- These p ecli ical fi di gs fu the suppo t the pote tial of IBIO-610 to imp ove body compositio , both as a sta dalo e the apy a d i combi atio with GLP-1 ecepto ago ists.
- iBio expects to i itiate fi st-i -huma t ials of IBIO-610 i the fi st half of 2027.
- Completed dosi g i the si gle asce di g dose (SAD) po tio of the fi st-i -huma Phase 1 cli ical t ial of IBIO-600, iBio’s lo g-acti g a ti-myostati a tibody bei g developed to p ese ve muscle a d imp ove body compositio .
- iBio a ticipates i te im Phase 1 data of the SAD study i the fi st qua te of 2027.
- The multiple asce di g dose po tio of the Phase 1 cli ical t ial is a ticipated to sta t i the fi st qua te of 2027.
- Pla s to pa ticipate i upcomi g scie tific a d i vesto co fe e ces, i cludi g:
- Gugge heim Healthca e I ovatio Co fe e ce: Novembe 9-11, 2026
- ObesityWeek 2026: Novembe 14-17, 2026
- P otei & A tibody E gi ee i g (PEGS) Eu ope 2026: Novembe 16-19, 2026
- Jeffe ies Global Healthca e Co fe e ce: Novembe 16-19, 2026
- Pipe Sa dle 38th A ual Healthca e Co fe e ce: Decembe 1-3, 2026
- Amyli -Based The apeutics Summit: Decembe 1-3, 2026
- Reve ues fo the th ee mo ths e ded Septembe 30, 2026 we e app oximately $1.1 millio , a i c ease of $1.0 ove the $0.1 millio i eve ue fo the th ee mo ths e ded Septembe 30, 2025.
- Resea ch a d Developme t (“R&D”) expe ses fo the th ee mo ths e ded Septembe 30, 2026 a d 2025 we e app oximately $6.7 millio a d $3.6 millio , espectively, a i c ease of app oximately $3.1 millio o app oximately 87%. The i c ease i R&D expe ses is p ima ily due to i c eased spe di g of app oximately $2.6 millio fo co sulta ts a d outside se vices suppo ti g ou R&D effo ts, i cludi g the IBIO-600 Phase 1 huma cli ical t ial, NHP studies a d CMC activities, a d a i c ease of app oximately $0.3 millio i pe so el costs as a esult of adva ci g esea ch activities fo ou IBIO-600, IBIO-610, a d IBIO-800 p og ams a d othe p ecli ical pipeli e assets.
- Ge e al a d Admi ist ative expe ses fo the th ee mo ths e ded Septembe 30, 2026 a d Septembe 30, 2025, we e app oximately $2.8 millio a d $2.5 millio , espectively, a i c ease of app oximately $0.3 millio o app oximately 10%. The i c ease is p ima ily att ibutable to a i c ease i pe so el costs a d legal fees.
- iBio held cash a d cash equivale ts a d i vestme ts i debt secu ities of app oximately $76.7 millio as of Septembe 30, 2026.
iBio (Nasdaq: IBIO) is a cli ical-stage biotech ology developi g lo g-acti g a tibody the apeutics fo obesity, ca diometabolic a d ca diopulmo a y diseases, ca ce , a d othe ha d-to-t eat diseases. Combi i g adva ced a tibody e gi ee i g with AI-d ive discove y, iBio is adva ci g a diffe e tiated pipeli e desig ed to delive sustai ed the apeutic effects a d add ess sig ifica t u met medical eeds. iBio’s missio is to t a sfo m d ug discove y, accele ate developme t timeli es, a d u lock ew possibilities i p ecisio medici e.
Fo mo e i fo matio , visit www.ibioi c.com o follow us o Li kedI .
This p ess elease co tai s fo wa d-looki g stateme ts withi the mea i g of the fede al secu ities laws. These stateme ts i clude, amo g othe s, stateme ts ega di g IBIO-610’s pote tial to delive high-quality weight loss a d p ovide impo ta t p ecli ical validatio ; iBio adva ci g towa d a IND-equivale t fili g fo IBIO-610 by the e d of 2026, with pla s to i itiate fi st-i -huma studies i the fi st half of 2027; adva ci g IBIO-600 i the multiple asce di g dose po tio of the Phase 1 t ial i the fi st qua te of 2027 a d p og essi g iBio’s p ecli ical p og ams that aim to add ess the e ti e spect um of ca diometabolic disease ca e; iBio helpi g people livi g with obesity achieve high-quality weight loss a d bette lo g-te m health; the pote tial that addi g IBIO-610 to GLP-1 the apy may imp ove the quality of weight loss by i c easi g the p opo tio of weight lost f om fat while p ese vi g muscle; i itiati g fi st-i -huma t ials of IBIO-610 i the fi st half of 2027; a ticipated i te im Phase 1 data of the SAD study i the fi st qua te of 2027; the multiple asce di g dose po tio of the Phase 1 cli ical t ial fo IBIO-600 a ticipated to sta t i the fi st qua te of 2027; a d iBio’s pla ed pa ticipatio i upcomi g co fe e ces. These stateme ts eflect iBio’s cu e t expectatio s a d assumptio s a d a e subject to isks a d u ce tai ties that could cause actual esults to diffe mate ially, i cludi g isks associated with meeti g a ticipated timeli es, i cludi g a IND-equivale t fili g fo IBIO-610 by the e d of 2026, i itiati g fi st-i -huma studies i the fi st half of 2027, adva ci g IBIO-600 i the multiple asce di g dose po tio of the Phase 1 t ial i the fi st qua te of 2027, i itiati g fi st-i -huma t ials of IBIO-610 i the fi st half of 2027 a d the multiple asce di g dose po tio of the Phase 1 cli ical t ial fo IBIO-600 sta ti g i the fi st qua te of 2027 cli ical t ial e ollme t a d executio , the possibility that p ecli ical fi di gs will ot be eplicated i huma s, p oduct developme t a d egulato y app oval, a d the othe isks desc ibed i iBio’s fili gs with the Secu ities a d Excha ge Commissio , i cludi g its A ual Repo t o Fo m 10-K fo the yea e ded Ju e 30, 2026, a d subseque t fili gs.
Fo wa d-looki g stateme ts speak o ly as of the date of this elease. iBio u de takes o obligatio to update them except as equi ed by law.
Matt Beckast pa t e smatthew.beck@ast pa t e s.com (917) 415-1750
Jaso B aco, Ph.D.Vale ce Commu icatio sjaso @vale cecomms.com
| (U audited; i thousa ds, except pe sha e amou ts) | Reve ue | $ | 1,075 | $ | 100 | Ope ati g expe ses: | Resea ch a d developme t | 6,650 | 3,550 | Ge e al a d admi ist ative | 2,763 | 2,501 | Total ope ati g expe ses | 9,413 | 6,051 | Ope ati g loss | (8,338 | ) | (5,951 | ) | Othe i come (expe se): | I te est i come | 787 | 265 | I te est expe se | — | (34 | ) | Total othe i come | 787 | 231 | Net loss befo e i come taxes | (7,551 | ) | (5,720 | ) | I come tax expe se | — | — | Net loss | $ | (7,551 | ) | $ | (5,720 | ) | Comp ehe sive loss: | Net loss | $ | (7,551 | ) | $ | (5,720 | ) | Othe comp ehe sive loss – u ealized loss o debt secu ities | (78 | ) | (15 | ) | Comp ehe sive loss | $ | (7,629 | ) | $ | (5,735 | ) | Loss pe commo sha e – basic a d diluted | $ | (0.05 | ) | $ | (0.11 | ) | Weighted-ave age commo sha es outsta di g – basic a d diluted – see Note 16 | 151,574 | 52,981 |
| (I thousa ds, except sha e a d pe sha e amou ts) | Septembe 30, | Ju e 30, | 2026 | 2026 | (U audited) | Assets | Cu e t assets: | Cash a d cash equivale ts | $ | 45,435 | $ | 56,395 | Accou ts eceivable – t ade, et of allowa ce fo c edit losses of $65 as of Septembe 30, 2026 a d Ju e 30, 2026 | 125 | — | I vestme ts i debt secu ities (adjusted cost $31,342 a d $31,689 as of Septembe 30, 2026 a d Ju e 30, 2026, espectively – see Note 6) | 31,219 | 31,644 | P omisso y ote eceivable a d acc ued i te est | 1,124 | 1,104 | P epaid expe ses a d othe cu e t assets | 3,336 | 3,078 | Total Cu e t Assets | 81,239 | 92,221 | Rest icted cash | 228 | 228 | Ope ati g lease ight-of-use asset, et of accumulated amo tizatio | 1,566 | 1,667 | Fixed assets, et of accumulated dep eciatio | 3,021 | 3,086 | I ta gible assets, et of accumulated amo tizatio | 2,570 | 1,825 | P epaid expe ses – o cu e t | — | 73 | Secu ity deposits | 27 | 10 | Total Assets | $ | 88,651 | $ | 99,110 | Liabilities a d Stockholde s’ Equity | Cu e t liabilities: | Accou ts payable | $ | 4,409 | $ | 4,423 | Acc ued expe ses | 3,404 | 5,626 | Ope ati g lease obligatio – cu e t po tio | 561 | 546 | Co t act liabilities | 200 | 1,150 | Total Cu e t Liabilities | 8,574 | 11,745 | Ope ati g lease obligatio – et of cu e t po tio | 1,507 | 1,652 | Total Liabilities | 10,081 | 13,397 | Stockholde s’ Equity | P efe ed Stock – $0.001 pa value; 1,000,000 sha es autho ized; 0 sha es issued a d outsta di g (see Note 15) | — | — | Commo Stock – $0.001 pa value; 275,000,000 sha es autho ized; 64,307,256 a d 55,698,561 sha es issued a d outsta di g as of Septembe 30, 2026 a d Ju e 30, 2026, espectively (see Note 15) | 64 | 56 | Additio al paid-i capital | 451,448 | 450,970 | Accumulated othe comp ehe sive loss | (123 | ) | (45 | ) | Accumulated deficit | (372,819 | ) | (365,268 | ) | Total Stockholde s’ Equity | 78,570 | 85,713 | Total Liabilities a d Stockholde s’ Equity | $ | 88,651 | $ | 99,110 |
